Drug-Resistant Tuberculosis
15
2
3
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 15 trials
100.0%
+13.4% vs benchmark
13%
2 trials in Phase 3/4
44%
4 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 9 completed trials
Clinical Trials (15)
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment
Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis
Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis
A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis
Evaluation of Centralised TB Assay Solutions
Behavior Change and Digital Health Interventions for Improved TB Treatment Outcomes
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
Rewards for Tuberculosis Contact Screening
Brief Bactericidal Activity of Anti-Tuberculosis Drugs